TRINETRA › Sectors › Healthcare
Eris Lifesciences Limited (ERIS) — share price, P/E and fundamentals
Eris Lifesciences Limited (NSE: ERIS) closed at ₹1,156.40 on 30 Oct 2026, -27.6% over one year, against a 52-week range of ₹1,069.00 – ₹1,740.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 26 Oct 2026) it reported revenue of ₹892 cr and net profit of ₹184 cr, a 20.6% net margin; revenue grew 12.6% and profit fell 9.0% year on year.
On four consecutive filed quarters its trailing P/E is 22.7; since 19 May 2025 its own P/E has ranged from 21.4 to 71.5 (median 53.6), and today's reading is higher than 0% of those 359 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 17.7%, ROCE 16.6%, debt-to-equity 0.57, Piotroski F-score 6 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 78% of 63 sector peers; PBT margin higher than 49% of 63 sector peers; ROE higher than 68% of 63 sector peers.
Key figures
| Last close | ₹1,156.40 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -9.3% / -15.8% / -27.6% |
| 52-week low – high | ₹1,069.00 – ₹1,740.00 |
| Market capitalisation | ₹16,039 cr |
| Trailing P/E | 22.7 |
| Price / book | 3.87 |
| EV / EBITDA | 16.3 |
| Earnings yield | 4.4% |
| TTM EPS | ₹51.02 |
| TTM net profit | ₹708 cr |
| Quarter revenue | ₹892 cr |
| Quarter net profit | ₹184 cr |
| Net margin | 20.6% |
| Revenue growth (YoY) | +12.6% |
| Profit growth (YoY) | -9.0% |
| Return on equity | 17.7% |
| ROCE | 16.6% |
| Debt / equity | 0.57 |
| Current ratio | 0.67 |
| Free cash flow | ₹417 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹6.6 cr |
Against Healthcare peers
| Metric | ERIS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 20.60 | 12.67 | 78 |
| PBT margin | 17.57 | 17.68 | 49 |
| ROE | 17.74 | 13.86 | 68 |
| ROCE | 16.59 | 17.26 | 49 |
| Debt / equity | 0.57 | 0.11 | 91 |
| FCF margin | 23.60 | -0.87 | 100 |
| Cash conversion | 1.93 | 1.25 | 80 |
| Trailing P/E | 22.67 | 43.26 | 9 |
Questions
What is the P/E ratio of Eris Lifesciences Limited?
Eris Lifesciences Limited's trailing P/E is 22.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 19 May 2025 its P/E has ranged 21.4–71.5.
What were Eris Lifesciences Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Eris Lifesciences Limited reported revenue of ₹892 cr and net profit of ₹184 cr (consolidated), filed with the exchange on 26 Oct 2026.
What is Eris Lifesciences Limited's ROE?
Return on equity is 17.7% based on the balance sheet dated 30 Sept 2026.
Does Eris Lifesciences Limited have debt?
Debt-to-equity is 0.57 on the balance sheet dated 30 Sept 2026.
What is ERIS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ERIS traded between ₹1,069.00 and ₹1,740.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.